Agency Information Collection Activities: Submission for OMB Review; Comment Request, 27756-27757 [2020-09961]

Download as PDF 27756 Federal Register / Vol. 85, No. 91 / Monday, May 11, 2020 / Notices The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, RFP 75N93019R00024, ‘‘Chemistry Center for Combating AntibioticResistant Bacteria (CC4CARB)’’. Date: June 9–10, 2020. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, 3G13, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Brenda Lange-Gustafson, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, 3G13, Rockville, MD 20852, 240–669–5047, bgustafson@niaid.nih.gov, (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 5, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–09977 Filed 5–8–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health khammond on DSKJM1Z7X2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which VerDate Sep<11>2014 17:05 May 08, 2020 Jkt 250001 would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel, HIV/AIDS Clinical Trial Units. Date: June 5–8, 2020. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G31, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Cynthia Louise De La Fuente, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G31, Rockville, MD 20852, 240–669–2740, delafuentecl@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: May 5, 2020. Tyeshia M. Roberson, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2020–09979 Filed 5–8–20; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, email or call the SAMHSA Reports Clearance Officer at carlos.graham@samhsa.hhs.gov or (240) 276–0361. Proposed Project: Program Evaluation for Prevention Contract (PEPC)— Strategic Prevention Framework for Prescription Drugs (SPF–Rx) Evaluation (OMB No. 0930–0377)—Revision The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ) aims to complete a cross-site evaluation of SAMHSA’s Strategic Prevention Framework for Prescription Drugs (SPF– Rx). SPF–Rx is designed to address PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 nonmedical use of prescription drugs as well as opioid overdoses by raising awareness about the dangers of sharing medications and by working with pharmaceutical and medical communities on the risks of overprescribing. The SPF–Rx program aims to promote collaboration between states/tribes and pharmaceutical and medical communities to understand the risks of overprescribing to youth ages 12–17 and adults 18 years of age and older. The program also aims to enhance capacity for, and access to, Prescription Drug Monitoring Program (PDMP) data for prevention purposes. This request for data collection includes a revision from previously approved OMB instruments. The SPF–Rx program’s indicators of success are reductions in opioid overdoses, reductions in prescription drug misuse, and improved use of PDMP data. Data collected through the tools described in this statement will be used for the national cross-site evaluation of SAMHSA’s SPF–Rx program. This package covers continued data collection through 2023. The PEPC team will systematically collect and maintain an Annual Implementation Instrument (AII) and Grantee and Community Level Outcomes data modules submitted by SPF–Rx grantees through the online Data Management System (DMS). SAMHSA is requesting approval for data collection for the SPF–Rx cross-site evaluation with the following instruments: • Annual Implementation Instrument (AII)—The AII is a survey instrument collected yearly to monitor state, tribal entity, and community-level performance, and to evaluate the effectiveness of the SPF–Rx program. This tool is completed by grantees and subrecipient community project directors, and provides process data related to funding use and effectiveness, organizational capacity, collaboration with community partners, data infrastructure, planned intervention targets, intervention implementation, evaluation, contextual factors, training and technical assistance (T/TA) needs, and sustainability. • Grantee-and Community-Level Outcomes Modules—These modules collect data on key SPF–Rx program outcomes, including opioid prescribing patterns and provider use of PDMP. Grantees will provide outcomes data at the grantee level for their state, tribal area, or jurisdiction, as well as at the community level for each of their subrecipient communities. • Grantee-Level Interview—This qualitative interview will be E:\FR\FM\11MYN1.SGM 11MYN1 27757 Federal Register / Vol. 85, No. 91 / Monday, May 11, 2020 / Notices administered at the end of the evaluation to obtain information from the grantee project directors on their programs, staffing, populations of focus, infrastructure, capacity, lessons learned, and collaboration. ANNUALIZED DATA COLLECTION BURDEN BY YEAR Number of respondents Instrument Total number of responses Hours per response Total burden hours Annual implementation instrument ...................................... Grantee-Level Outcomes Module ........................................ Community-Level Outcomes Module ................................... Grantee-Level Interview ....................................................... 148 25 25 25 1 1 4.92 1 148 25 123 25 4 2.5 1.25 1.5 592 62.5 153.75 37.5 FY2021 ......................................................................... Annual Implementation Instrument ...................................... Grantee-Level Outcomes Module ........................................ Community-Level Outcomes Module ................................... 223 148 25 25 ........................ 1 1 4.92 321 148 25 123 ........................ 4 2.5 1.25 845.75 592 62.5 154.75 FY2022 ......................................................................... Annual Implementation Instrument ...................................... Grantee-Level Outcomes Module ........................................ Community-Level Outcomes Module ................................... 198 39 7 7 ........................ 1 1 4.57 296 39 7 32 ........................ 4 2.5 1.25 808.25 156 17.5 40 FY2023 ......................................................................... 53 ........................ 78 ........................ 213.5 Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. Carlos Graham, Social Science Analyst. [FR Doc. 2020–09961 Filed 5–8–20; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID FEMA–2008–0010] Board of Visitors for the National Fire Academy; Meeting Federal Emergency Management Agency, DHS. ACTION: Committee Management; Notice of Open Federal Advisory Committee Meeting. AGENCY: The Board of Visitors for the National Fire Academy (Board) will meet via teleconference on Tuesday, June 9, 2020. The meeting will be open to the public. DATES: The meeting will take place on Tuesday, June 9, 2020, 1:30 to 3:30 p.m. EDT. Please note that the meeting may close early if the Board has completed its business. SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES Responses per respondent VerDate Sep<11>2014 17:05 May 08, 2020 Jkt 250001 Members of the public who wish to participate in the teleconference should contact Deborah Gartrell-Kemp as listed in the FOR FURTHER INFORMATION CONTACT section by close of business June 1, 2020, to obtain the callin number and access code for the June 9 teleconference meeting. For more information on services for individuals with disabilities or to request special assistance, contact Deborah GartrellKemp as soon as possible. To facilitate public participation, we are inviting public comment on the issues to be considered by the Board as listed in the SUPPLEMENTARY INFORMATION section. Participants seeking to have their comments considered during the meeting should submit them in advance or during the public comment segment. Comments submitted up to 30 days after the meeting will be included in the public record and may be considered at the next meeting. Comments submitted in advance must be identified by Docket ID FEMA–2008–0010 and may be submitted by one of the following methods: • Federal eRulemaking Portal: http:// www.regulations.gov. Follow the instructions for submitting comments. • Mail/Hand Delivery: Deborah Gartrell-Kemp, 16825 South Seton Avenue, Emmitsburg, Maryland 21727, post-marked no later than May 23, 2020, for consideration at the June 9, 2020, meeting. Instructions: All submissions received must include the words ‘‘Federal Emergency Management Agency’’ and the Docket ID for this action. Comments received will be posted without alteration at http://www.regulations.gov, ADDRESSES: PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 including any personal information provided. Docket: For access to the docket to read background documents or comments received by the National Fire Academy Board of Visitors, go to http:// www.regulations.gov, click on ‘‘Advanced Search,’’ then enter ‘‘FEMA–2008–0010’’ in the ‘‘By Docket ID’’ box, then select ‘‘FEMA’’ under ‘‘By Agency,’’ and then click ‘‘Search.’’ FOR FURTHER INFORMATION CONTACT: Alternate Designated Federal Officer: Kirby E. Kiefer, telephone (301) 447– 1117, email Kirby.Kiefer@fema.dhs.gov. Logistical Information: Deborah Gartrell-Kemp, telephone (301) 447– 7230, email Deborah.GartrellKemp@ fema.dhs.gov. The Board will meet via teleconference on Tuesday, June 9, 2020. The meeting will be open to the public. Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. Appendix. SUPPLEMENTARY INFORMATION: Purpose of the Board The purpose of the Board is to review annually the programs of the National Fire Academy (Academy) and advise the Administrator of the Federal Emergency Management Agency (FEMA), through the United States Fire Administrator, on the operation of the Academy and any improvements therein that the Board deems appropriate. In carrying out its responsibilities, the Board examines Academy programs to determine whether these programs further the basic missions that are approved by the Administrator of FEMA, examines the physical plant of the Academy to E:\FR\FM\11MYN1.SGM 11MYN1

Agencies

[Federal Register Volume 85, Number 91 (Monday, May 11, 2020)]
[Notices]
[Pages 27756-27757]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09961]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration


Agency Information Collection Activities: Submission for OMB 
Review; Comment Request

    Periodically, the Substance Abuse and Mental Health Services 
Administration (SAMHSA) will publish a summary of information 
collection requests under OMB review, in compliance with the Paperwork 
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these 
documents, email or call the SAMHSA Reports Clearance Officer at 
[email protected] or (240) 276-0361.

Proposed Project: Program Evaluation for Prevention Contract (PEPC)--
Strategic Prevention Framework for Prescription Drugs (SPF-Rx) 
Evaluation (OMB No. 0930-0377)--Revision

    The Substance Abuse and Mental Health Services Administration's 
(SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ) 
aims to complete a cross-site evaluation of SAMHSA's Strategic 
Prevention Framework for Prescription Drugs (SPF-Rx). SPF-Rx is 
designed to address nonmedical use of prescription drugs as well as 
opioid overdoses by raising awareness about the dangers of sharing 
medications and by working with pharmaceutical and medical communities 
on the risks of overprescribing. The SPF-Rx program aims to promote 
collaboration between states/tribes and pharmaceutical and medical 
communities to understand the risks of overprescribing to youth ages 
12-17 and adults 18 years of age and older. The program also aims to 
enhance capacity for, and access to, Prescription Drug Monitoring 
Program (PDMP) data for prevention purposes. This request for data 
collection includes a revision from previously approved OMB 
instruments.
    The SPF-Rx program's indicators of success are reductions in opioid 
overdoses, reductions in prescription drug misuse, and improved use of 
PDMP data. Data collected through the tools described in this statement 
will be used for the national cross-site evaluation of SAMHSA's SPF-Rx 
program. This package covers continued data collection through 2023. 
The PEPC team will systematically collect and maintain an Annual 
Implementation Instrument (AII) and Grantee and Community Level 
Outcomes data modules submitted by SPF-Rx grantees through the online 
Data Management System (DMS).
    SAMHSA is requesting approval for data collection for the SPF-Rx 
cross-site evaluation with the following instruments:
     Annual Implementation Instrument (AII)--The AII is a 
survey instrument collected yearly to monitor state, tribal entity, and 
community-level performance, and to evaluate the effectiveness of the 
SPF-Rx program. This tool is completed by grantees and subrecipient 
community project directors, and provides process data related to 
funding use and effectiveness, organizational capacity, collaboration 
with community partners, data infrastructure, planned intervention 
targets, intervention implementation, evaluation, contextual factors, 
training and technical assistance (T/TA) needs, and sustainability.
     Grantee-and Community-Level Outcomes Modules--These 
modules collect data on key SPF-Rx program outcomes, including opioid 
prescribing patterns and provider use of PDMP. Grantees will provide 
outcomes data at the grantee level for their state, tribal area, or 
jurisdiction, as well as at the community level for each of their 
subrecipient communities.
     Grantee-Level Interview--This qualitative interview will 
be

[[Page 27757]]

administered at the end of the evaluation to obtain information from 
the grantee project directors on their programs, staffing, populations 
of focus, infrastructure, capacity, lessons learned, and collaboration.

                                    Annualized Data Collection Burden by Year
----------------------------------------------------------------------------------------------------------------
                                     Number of     Responses per   Total number      Hours per     Total burden
           Instrument               respondents     respondent     of responses      response          hours
----------------------------------------------------------------------------------------------------------------
Annual implementation instrument             148               1             148               4             592
Grantee-Level Outcomes Module...              25               1              25             2.5            62.5
Community-Level Outcomes Module.              25            4.92             123            1.25          153.75
Grantee-Level Interview.........              25               1              25             1.5            37.5
                                 -------------------------------------------------------------------------------
    FY2021......................             223  ..............             321  ..............          845.75
Annual Implementation Instrument             148               1             148               4             592
Grantee-Level Outcomes Module...              25               1              25             2.5            62.5
Community-Level Outcomes Module.              25            4.92             123            1.25          154.75
                                 -------------------------------------------------------------------------------
    FY2022......................             198  ..............             296  ..............          808.25
Annual Implementation Instrument              39               1              39               4             156
Grantee-Level Outcomes Module...               7               1               7             2.5            17.5
Community-Level Outcomes Module.               7            4.57              32            1.25              40
                                 -------------------------------------------------------------------------------
    FY2023......................              53  ..............              78  ..............           213.5
----------------------------------------------------------------------------------------------------------------

    Written comments and recommendations for the proposed information 
collection should be sent within 30 days of publication of this notice 
to www.reginfo.gov/public/do/PRAMain. Find this particular information 
collection by selecting ``Currently under 30-day Review--Open for 
Public Comments'' or by using the search function.

Carlos Graham,
Social Science Analyst.
[FR Doc. 2020-09961 Filed 5-8-20; 8:45 am]
BILLING CODE 4162-20-P